Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide and a leading cause of death in cirrhosis. The prognosis in HCC is poor, with …

Background Clinical benefit of neoadjuvant immunotherapy in resectable esophageal
squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and …

Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …

Hepatocellular carcinoma (HCC), particularly when accompanied by microvascular invasion
(MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy …

Surgical resection remains a mainstay in the treatment of malignant solid tumors. However,
the use of neoadjuvant treatments, including chemotherapy, radiotherapy, phototherapy …

Abstract Programmed death receptor-1 (PD-1) blockade have achieved some efficacy but
only in a fraction of patients with hepatocellular carcinoma (HCC). Programmed cell death 1 …

The last 10 years have revolutionized our basic understanding of nonalcoholic fatty liver
disease and consequent liver cancer. It has become clear that several innate and adaptive …

Background & Aims The use of immune checkpoint inhibitors (ICIs) in patients with
advanced hepatocellular carcinoma (HCC) has become widespread with encouraging …

Background Surgical resection of early stage hepatocellular carcinoma is standard clinical
practice; however, most tumours recur despite surgery, and no perioperative intervention …